Merck & Co., Inc. vs Nokia Corp — how do they compare? Merck & Co., Inc. trades at $144.69 (market cap $351.28B), while Nokia Corp trades at $10.39 (market cap $56.99B). The key difference: Merck & Co., Inc. is far larger — about 6.2× Nokia Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nokia Corp for 66 Days on average.
| MRK | NOK | |
|---|---|---|
Market Cap | $351.28B | $56.99B |
Volume | 7,969,665 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $156.43 | $16.83 |
52-Week Low | $82.49 | $5.18 |
Typical Hold Time | 98 Days | 66 Days |
Enterprise Value | $398.04B | $55.01B |
Dividend Yield | 2.39% | 1.61% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia for growth in AI and telecommunications infrastructure.
The outlook for Nokia is positive, supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings. Key opportunities include expanding AI and cloud orders, which grew 105% in Q2 2026. Risks involve competitive pressures in telecom equipment, reliance on global infrastructure spending, and volatility in net cash flow, which turned negative in 2025. Execution on partnerships and margin expansion are critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →